<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455935</url>
  </required_header>
  <id_info>
    <org_study_id>NEU 3200411A</org_study_id>
    <nct_id>NCT01455935</nct_id>
  </id_info>
  <brief_title>Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention</brief_title>
  <acronym>WASSABI</acronym>
  <official_title>Wake up Symptomatic Stroke in Acute Brain Ischemia (WASSABI) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jacobs Neurological Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University at Buffalo Neurosurgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jacobs Neurological Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to study the safety and the effectiveness of using CT Perfusion
      studies as an indicator to treat stroke patients with unknown time of onset.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>Modified Rankin Scale (mRS) 90 days post treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>24 hour</time_frame>
    <description>National Institute of Health Stroke Scale (NIHSS) 24 hours post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>3-29 day</time_frame>
    <description>National Institute of Health Stroke Scale (NIHSS) at discharge (3-29 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>30 post treatment</time_frame>
    <description>Modified Rankin Scale (mRS) at 30 days post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis In Myocardial Infarction (TIMI) Flow</measure>
    <time_frame>Pre - up to1 hour prior to procedure and post will be up to1 hour after completion of procedure</time_frame>
    <description>Thrombolysis In Myocardial Infarction (TIMI) flow pre and post the intervention as an indicator of revascularization rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thomboylsis in Cerebral Ischemia (TICI) flow</measure>
    <time_frame>Pre - will be no more than 1 hour prior to procedure and post will be no more then 1 hour after completion of procedure</time_frame>
    <description>Thomboylsis in Cerebral Ischemia (TICI) flow pre and post intervention as an indicator of revascularization rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptomatic intracranial Hemorrhage (ICH)</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence of symptomatic symptomatic intracranial Hemorrhage (ICH) within 72 hours of intervention defined by ECASSIII as 4 points worsening in NIHSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>30 Days</time_frame>
    <description>at 30 Day visit National Institute of Health Stroke Scale (NIHSS) will be assessed</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Medical Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Current standard of care per the latest stroke guidelines
Permissive Hypertension up to 220
Antipletelets therapy:
ASA 81 mg PO daily or
Plavix 75 mg PO daily or
Aggrenox 225mg PO twice daily
Anti-inflammatory therapy:
Lipitor 80 mg PO daily or
Crestor 20 mg PO daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Thrombolysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full dose Intravenous thrombolysis
0.9 mg/kg
Maximum dose is 90 mg
10% of the dose will be given over one minute
90% of the dose will be infused over 1 hour
Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications
Neuro checks every 5 minutes during the infusion
Neuro checks every hour after the infusion for 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra-Arterial Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Choice of therapy per experienced Endovascular surgeon and includes:
Intra arterial Activase (Maximum dose of 22 mg)
MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)
PENUMBRA device (no standard time frame for how long the procedure takes)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-platelets and statin</intervention_name>
    <arm_group_label>Medical Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alteplase</intervention_name>
    <description>Full dose Intravenous thrombolysis
0.9 mg/kg
Maximum dose is 90 mg
10% of the dose will be given over one minute
90% of the dose will be infused over 1 hour
Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications
Neuro checks every 5 minutes during the infusion
Neuro checks every hour after the infusion for 24 hours</description>
    <arm_group_label>Intravenous Thrombolysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intra arterial intervention</intervention_name>
    <description>Intra arterial Activase (Maximum dose of 22 mg)
MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)
PENUMBRA device (no standard time frame for how long the procedure takes)</description>
    <arm_group_label>Intra-Arterial Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria: To be eligible for entry into this study, candidates must meet all of
        the following eligibility criteria at the time of Emergency Department presentation:

          1. Age: 18-80 years old

          2. Ischemic Wake Up Stroke (Unknown time of onset but less than 24 hours since last seen
             normal)

          3. National Institute of Health Stroke Scale (NIHSS) 8-22

          4. Evidence of penumbra on Computed Tomography Perfusion(CTP) as mentioned above

          5. Alberta Stroke Program Early Computed Tomography (CT) Score (ASPECTS 7 or more)

          6. Signed informed consent

        Exclusion Criteria:

        Exclusion Criteria: Potential study patients will be excluded from study entry if any of
        the following exclusion criteria exist at the time of screening:

          1. Evidence of intracranial hemorrhage (Intracerebral hematoma, intraventricular
             hemorrhage, subarachnoid hemorrhage (SAH), epidural hemorrhage, acute or chronic
             subdural hematoma (SDH)) on the baseline CT

          2. Historical Modified Rankin Scale (mRS) of â‰¥2

          3. National Institute of Health Stroke Scale (NIHSS)&lt;8 at the time of treatment

          4. Positive pregnancy test in women at age of childbearing

          5. Intracranial or intraspinal surgery within 3 months

          6. Stroke or serious head injury within 3 months

          7. History of intracranial hemorrhage

          8. Uncontrolled hypertension at time of treatment (eg, &gt;185 mm Hg systolic or &gt;110 mm Hg
             diastolic)

          9. Seizure at the onset of stroke

         10. Active internal bleeding

         11. Intracranial neoplasm

         12. Arteriovenous malformation or aneurysm

         13. Clinical presentation suggesting post-MI pericarditis

         14. Known bleeding diathesis including but not limited to current use of oral
             anticoagulants producing an Internation normalized ratio (INR) &gt;1.7

         15. Internation normalized ratio (INR) &gt;1.7

         16. Administration of heparin within 48 hours preceding the onset of stroke with an
             elevated activated Partial Thromboplastin Time(aPTT) at presentation

         17. Platelet count &lt;100,000/mm

         18. Major surgery within 2 weeks

         19. GastroIntestinal (GI) or urinary tract hemorrhage within 3 weeks

         20. Aggressive treatment required to lower blood pressure

         21. Glucose level &lt;50 or &gt;400 mg/dL

         22. Arterial puncture at a noncompressible site or lumbar puncture within 1 week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elad I Levy, MD</last_name>
    <role>Study Director</role>
    <affiliation>University at Buffalo Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tareq Kass-Hout, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jacobs Neurological Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tareq Kass-Hout, MD</last_name>
    <phone>716-887-5548</phone>
    <email>kasshouttareq@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Millard Fillmore Gates Circle Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annemarie Crumlish</last_name>
      <phone>716-887-5548</phone>
      <email>acrumlish@thejni.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Kass-Hout, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elad Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adnan H Siddiqui, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth V Snyder, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>L N Hopkins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert N Sawyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marilou Ching, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Janicke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>March 29, 2012</last_update_submitted>
  <last_update_submitted_qc>March 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jacobs Neurological Institute</investigator_affiliation>
    <investigator_full_name>Tareq Kass-Hout</investigator_full_name>
    <investigator_title>Chief Vascular/Neurology Resident in charge of stroke</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

